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Vitamin A is an important regulator of cell
differentiation and function. In its absence, a
number of cells in vivo undergo squamous
metaplasia (Wolbach & Howe, 1925) which in the
case of mouse prostate in vitro may be reversed by
vitamin A (Laznitski, 1963). This type of cell
transformation is though to indicate neoplastic
potential, a situation clearly evident in the vitamin
A deficient rat where a higher rate of spontaneous
carcinomas is detected (Fujimaki, 1926).
There is evidence to suggest that vitamin A
(retinol) may mediate its biological actions through
cellular retinol binding protein (cRBP) which binds
the ligand specifically and with high affinity (Ong &
Chytil, 1975, 1978). cRBP may serve to deliver
retinol from the cytoplasm to nuclear acceptor sites
where it affects genetic read out (Liau et al., 1981).
The presence of cRBP in human (benign)
hyperplastic prostate (BPH) has been reported by
this laboratory (Boyd et al., 1984). The protein
binds retinol with high affinity (35nM) and shows
similar characteristics to the component analysed in
other tissues (Bashor et al., 1973).
Reports from several laboratories suggest that the
expression of cRBP in malignancy may be altered.
In this respect, examination of epidermoid
carcinomas of the oral cavity and oropharynx
revealed cRBP levels to be higher in the malignancy
than in normal adjacent tissue (Ong et al., 1982). In
another study (Palan & Romney, 1980) reduced
levels of cRBP were reported in a number of
human tumours including lungs, ovaries and
endometrium. However, to the knowledge of these
workers, no study has yet been undertaken to
compare cRBP levels in human hyperplastic and
malignant prostate (CaP).
In this investigation, we have compared retinol
binding in human, benign and malignant prostates,
the results ofwhich are presented herein.
11,12 (n)-[3H] vitamin A free alcohol (all trans-
retinol) (sp. act.=43Cimmol-1) was purchased
from Amersham, Bucks, UK. Radioactive retinol
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was checked for purity every two weeks as
described previously (Boyd et al., 1984). All trans-
retinol (unlabelled ) was obtained from Sigma
Chemicals, Poole, Dorset, UK. All retinoids were
stored in ethanol solution, under nitrogen, in the
dark at -20°C. Other chemicals were of analytical
grade and obtained from Sigma, BDH, Poole,
Dorset, UK or Fisons, Leicester, UK. The
following buffers were used in these studies; TEDG
containing Tris 10mM, EDTA 1.5mM,
dithiothreitol 1.0mM, glycerol 10% (v/v) pH 7.4;
DCC containing dextran 0.025%, gelatin 0.1%,
activated charcoal 0.25% (w/v) in TED pH 7.4
buffer.
The patients entered in the present study were in
the age range 50-70 years. None of the cancer
patients had received any therapy (endocrine,
radiation etc.) prior to entry into this study. Prior
to the prostatectomy malignant tumours were
clinically staged by digital palpation using the
TNM system (Harmer, 1978). Incidental tumours
(To) and those clinically staged as T1 were excluded
from this study on the grounds that the portion of
gland assessed as malignant may be un-
representative of that selected for scientific work.
Prostate tissues were removed by trans-urethral
resection. Large uncharred prostatic chippings were
selected for our biochemical studies and transported
to the laboratory in ice-cold saline (0.9% w/v). A
portion of each chipping was retained for
histological analysis and assigned a Gleason Score
(Gleason, 1966) by the pathologist. Specimens used
for biochemical studies were snap frozen in liquid
nitrogen and stored at -70°C until required for
further analysis. In this study, a total of 16
hyperplastic and 15 malignant glands were assessed
for retinol binding.
The following procedures were carried out at
4°C. Prostate tissue (0.5-2.0g) was finely minced
with scissors and pulverised for 20sec in a Teflon
vial pre-cooled at -20°C using a Mikro-
dismembrator II (B. Braun, Melsungen AG, FRG).
The tissue was homogenised in 5-10 vol of TEDG
buffer as described previously (Boyd et al., 1984)
and ultracentrifuged at 100,000g for 1 h to obtain
the cytosol fraction.
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The retinol binding assay for cRBP was as
described previously (Boyd et al., 1984) but with
minor modifications. Briefly cytosol (protein
concentration 0.5mgml-1) was incubated in
triplicate at 4°C for 4h with [3H]retinol (10-7M)
in the presence and absence of unlabelled
competitor in 100 fold excess. Preliminary studies
had established the reproducibility of the assay;
inter and intra assay variations were <15%. In
addition, the specific binding of [3H]retinol was
found to be linear over a protein concentration
range of 0.1-1.0mgm.-1 and unaffected by either
freezing or storage of tissue at -70°C for up to 8
weeks.
After incubation with radio-ligand, cytosol was
treated with charcoal pellets (Boyd et al., 1984) to
remove unbound ligand, and finally counted for
radioactivity in 6ml of scintillation cocktail.
Non specific binding was corrected for, by
subtracting the radioactivity bound in the presence
of unlabelled retinol from that observed in the
absence of competitor. Control experiments had
shown that charcoal treatment removed over 99.5%
of free [3H]retinol from buffer and that remaining
radioactivity in no way interfered with the
measurement ofprostate cRBP.
Cytosol protein was assayed by the method of
Bradford (1976) using BSA as standard. The
difference in cRBP levels between benign and
malignant prostates was tested for statistical
significance by the Mann-Whitney U-test.
Hyperplastic prostate cytosol bound an average
of 4.0+1.6pmol of [3H]retinol per mg of protein
(Figure 1) (range: 1.9-8.4pmolml- protein). In
contrast less retinol (1.7+1.6pmolmg-1; range: 0-
6.5pmolmg-t protein) was specifically bound by
the malignant gland. In spite of an overlap between
the two groups there was a statistically significant
difference between the levels of cRBP in BPH and
CaP (P<0.01). Although all benign prostates
asayed for cRBP were found to be positive, this
was not the case in malignancy where 3/15 glands
were devoid of retinol binding, or at least below the
detection limits of the assay (100fmolmg-1).
In contrast to the differences observed between
BPH and CaP, these workers could find no
relationship between the levels of cRBP and
histological differentiation. In fact, similar amounts
of [3H]retinol were bound in well (Gleason sum 3-
4; 1.0+0.3pmolmg-1) and poorly differentiated
(Gleason sum 7-8; 1.1 ± 1.5pmolmg -1) tumours.
Data presented in this report suggest that
malignant prostate has a decreased ability to bind
retinol when compared with the benign,
hyperplastic gland. Suppressed retinol binding was
also found in a number of other human
malignancies including lung, ovarian and breast as
reported by Palan & Romney (1980). These data
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Figure 1 The cytosol fraction was prepared from
hyperplastic and malignant prostates and adjusted to
0.5mg protein ml-'. Subcellular fraction was assayed
for [3H]retinol binding as described in the text and
non specified binding corrected for. Data are expressed
as individual values. Continuous lines represented
mean values of the group: s.d. are indicated by
discontinuous lines.
were interpreted to mean fewer copies of cR_BP per
cell although no evidence was presented to support
such a contention. The possibility exists that
decreased binding of radiolabelled ligand may
reflect other factors eg:- (1) alteration of the cRBP
molecule with a reduced binding affinity for ligand.
(2) the presence of interfering endogenous retinol.
(3) enzymatic inactivation of cRBP. In this study
we found no alteration in the dissociation constant
(Kd) for retinol binding in prostate cancer
(Kd=31 + 15nM - data not shown). Thus, it would
seem unlikely that endogenous ligand and/or
alteration in the cRBP molecule can account for
our observations of suppressed binding in
malignancy. Also, since various enzyme inhibitors
including aprotinin, phenylmethyl-sulphonyl-
fluoride and sodium molybdate did not augment
radioligand binding in he prostate subcellular
fraction (data not shown), it is unlikely that the
difference in cRBP values between both sets of
tissues is a consequence of enhanced inactivation of
the macromolecule in prostate cancer. For these
reasons the possibility that prostate cRBP is being
expressed in reduced amounts in cancerous tissue
must be entertained. Such a concept is not novel; a
number ofproteins in a variety ofcancers are either
re-expressed from foetal development eg.
carcinoembryonic antigen (Hall et al., 1973) or
masked as cellular retinoic acid binding protein is
in anaplastic breast cancer.
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In view of the reduced levels of cRBP in
malignant tissue compared to BPH, it was
surprising not to find any correlation between the
levels of these binding sites and the histological
differentiation of the tumour. Similar observations
were made by Mehta et al. (1982) when
investigating retinoic acid binding in human breast
cancer.
The aetiological significance of these findings
with regard to prostate malignancy can only be
speculated on. Perhaps noteworthy is that such
changes do not necessarily infer a particular
requirement by the malignant cell for vitamin A
(Abelev, 1971). On the other hand, the possibility
exists that these data may be of prognostic
significance. In this regard low retinol binding in
patients with BPH could be used to identify those,
who, in time would progress to malignancy.
This work was supported by grants from the University of
Edinburgh and the Cancer Research Campaign.
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